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Background and PurposeaaErythropoietin (Epo), originally recognized for its central role in 
erythropoiesis, has been shown to improve the outcomes in patients with various neurological 
disorders. The aim of this study was to elucidate the Epo expression pattern in the spinal cords 
of Lewis rats with experimental autoimmune encephalomyelitis (EAE) and to assess the systemic 
effect of Epo during the course of EAE. 
MethodsaaWe used an EAE model induced in Lewis rats by immunization with myelin basic 
protein. Immunized rats were given recombinant human Epo (rhEpo) intraperitoneally at a 
dose of 5,000 U/kg for 7 consecutive days, either starting on day 3 post-immunization (five 
rats) or on the day of clinical symptom onset (score ≥1, five rats). After immunization, the rats 
were observed daily for clinical signs of EAE. Epo expression was investigated by Western 
blot analysis and immunohistochemistry. 
ResultsaaWestern blot analysis showed that, Epo expression was significantly elevated relative 
to control in the rat spinal cord during the peak stage of EAE (p<0.05), and then decreased 
thereafter. Immunohistochemistry demonstrated that Epo was expressed in some neurons and 
glial cells. Epo immunoreactivity was detected in ED1-positive macrophages and astrocytes in 
EAE lesions. Furthermore, we found that the intraperitoneal administration of rhEpo reduced 
both the disease severity and duration of paralysis in EAE rats, and reduced macrophage activity 
and increased Epo activity. 
ConclusionsaaBased on these findings, we postulate that Epo expression begins to increase at 
the start of EAE and that rhEpo administration leads to functional recovery from EAE paralysis. 
  J Clin Neurol 2009;5:39-45
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Introduction 
 
Erythropoietin (Epo) was initially identified as a hematopo-
ietic growth factor and has been used extensively for the 
treatment of anemia in humans. Epo has recently received 
considerable attention due to the unexpected finding that it 
can exert broad neuroprotective effects in a variety of neuro-
logical disorders.
1-3 The Epo receptor is widely expressed in 
most cerebral cell types, including neurons, microglial cells, 
and astrocytes.
4 Epo and its receptor are required for normal 
brain development and the regulation of neurogenesis in the 
central nervous system (CNS).
5,6 Neurons can produce Epo 
in response to hypoxia/ischemia, trauma, and immune- me-
diated inflammation.
7-9 The increased immunoreactivity for 
Epo in the CNS of superoxide dismutase (SOD1) transgenic 
mice suggests interventional strategies to alleviate motor 
neuron degeneration in human amyotrophic lateral sclerosis.
10 
However, such immunoreactivity has not been investigated in 
rats with experimental autoimmune encephalomyelitis (EAE). 
Multiple sclerosis (MS) is a chronic autoimmune disease 
of the CNS associated with demyelination, inflammation and 
axonal loss. Several cytokines, including anti-inflammatory 
cytokines and inhibitors of interleukin 1 (IL-1), and tumor 
necrosis factor (TNF), have shown some efficacy in reducing  
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the severity of EAE, in an animal model of MS, but none 
have been shown to be clinically effective. Systemically ad-
ministered Epo can delay the onset of EAE and decrease its 
clinical score.
11,12 Epo also reduces axonal damage, inflam-
matory cell infiltration and demyelination, and blood-brain- 
barrier leakage in EAE.
13 In addition, Epo exerts an anti-in-
flammatory effect on the CNS in EAE by delaying or reducing 
the increase in pro-inflammatory cytokines such as TNF-α, 
IL-6, IL-1β, and IL-1Ra.
11,14 
The mechanisms underlying the beneficial effects of Epo 
on the progression of EAE are not fully understood. In ad-
dition, little is known about the changes that take place in the 
Epo protein during EAE pathogenesis. The aim of this study 
was to elucidate the Epo expression pattern in the spinal cords 
of Lewis rats with EAE and to assess the systemic effects of 
Epo during the course of EAE. 
 
Methods 
 
Animals 
Lewis rats were obtained from Harlan (Indianapolis, IN) and 
bred in our animal facility. Only male rats (7-8 weeks old; 
160-200 g) were used in this study. All experiments followed 
the accepted ethical guidelines. 
 
Induction of experimental autoimmune  
encephalomyelitis 
The footpads of both hind feet of rats in the EAE group were 
injected with 100 μL of an emulsion that contained equal parts 
of myelin basic protein (MBP)(1 mg/mL) and complete 
Freund’s adjuvant (CFA) supplemented with Mycobacterium 
tuberculosis H37Ra (5 mg/mL)(Difco, Detroit, MI). Control 
rats were immunized with CFA alone. After immunization, 
the rats were observed daily for clinical signs of EAE. EAE 
progression was divided into seven clinical stages: Grade 0 
(G.0), no signs; G.1, floppy tail; G.2, mild paraparesis; G.3, 
severe paraparesis; G.4, tetraparesis; G.5, moribund condition 
or death; and R.0, recovery. 
 
Antibodies 
Rabbit polyclonal anti-Epo antibody was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal 
anti-β-actin and mouse anti-glial fibrillary acidic protein 
(GFAP) were obtained from Sigma (St. Louis, MO). ED1 
was obtained from Serotec (London, UK).  
 
Tissue sampling 
The rats were sacrificed under ether anesthesia. The spinal 
cords were dissected from rats in each group at 12-14 and 21 
days post-immunization (PI)(n=5 rats/group), corresponding 
to the peak (G.3, day 12-14 PI) and recovery (R.0, day 21 PI) 
stages of EAE, respectively. Sections were cut on a cryostat 
in the transverse plane through the lumbar spinal cord, and 
every fifth section was selected for histochemistry against 
different antigens, or hematoxylin and eosin staining. Spinal 
cord samples were processed for embedding in paraffin wax 
after fixation in 4% paraformaldehyde in phosphate-buffered 
saline (PBS, pH 7.4). Additional spinal cord samples were 
snap-frozen and stored for immunoblot analysis. 
 
Western blot analysis 
Spinal cord tissue was homogenized in a modified radioim-
munoprecipitation assay buffer {20 mM Tris, (pH 7.5), 150 
mM NaCl, 1% Triton-X 100, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 1% NP-40, 10 mM NaF, 1 
mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 1 mM PMSF, 10 
μg/mL aprotinin, and 10 μg/mL leupeptin} using 20 strokes in 
a homogenizer. The homogenate was transferred to mi-
crotubes and centrifuged at 14,000 rpm for 20 min, and the 
supernatant was harvested. 
For the immunoblot assay, supernatant samples containing 
40 μg of protein each were loaded into individual lanes of a 
10% sodium dodecyl (lauryl) sulfate-polyacrylamide gel, 
electrophoresed, and immunoblotted onto nitrocellulose mem-
branes (Schleicher and Schuell, Keene, NH). The residual 
binding sites on the membrane were blocked by incubation 
with 5% nonfat milk in Tris-buffered saline {TBS; 10 mM 
Tris-HCl (pH 7.4), and 150 mM NaCl} for 1 h. The mem-
brane was then incubated with rabbit polyclonal anti-Epo 
(1 : 1,000 dilution) antibody for 2 h. The membranes were 
washed three times in TBS containing 0.1% Tween 20 and 
incubated with horseradish peroxidase-conjugated anti-mouse 
IgG (Vector, Burlingame, CA) for 1 h. Bound antibodies were 
detected using a chemiluminescent substrate (WEST-one
TM 
Kit; iNtRON Biotech, Gyeonggi, Korea) according to the 
manufacturer’s instructions. After imaging, the membranes 
were stripped and reprobed using anti-β-actin antibody. The 
optical density (per mm
2) of each band was measured with a 
scanning laser densitometer (GS-700, Bio-Rad, Hercules, CA), 
and the obtained data are presented here as mean±SEM values. 
The ratios of the density of the Epo band relative to that of 
the β-actin band, were compared using Molecular Analyst 
software (Bio-Rad). 
The data were analyzed using one-way analysis of variance 
(ANOVA) followed by the Student-Newman-Keuls post-hoc 
test for multiple comparisons. In all cases, p<0.05 was con-
sidered statistically significant. 
 
Immunohistochemistry 
Briefly, paraffin-embedded spinal cords (5-μm sections) were  
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deparaffinized by treatment with citrate buffer (0.01 M, pH 
6.0) in a microwave oven for 5 min. The sections were washed 
three times with PBS, and then treated with 0.3% hydrogen 
peroxide in methyl alcohol for 20 min to block endogenous 
peroxidase activity. 
The sections were washed three washes with PBS, and 
then incubated with 10% normal goat serum followed by 
rabbit polyclonal anti-Epo. Immunoreactivity was visualized 
using the avidin-biotin peroxidase reaction (Vector Elite kit, 
Vector). Peroxidase was developed using a diaminobenzidine 
substrate kit (Vector). Sections were counterstained with he-
matoxylin before mounting. As a control, the primary antisera 
were omitted from a few test sections in each experiment.   
Epo expression was examined using double immunofluo-
rescence with cell-type-specific markers, including ED1 for 
monocyte-like macrophages, and anti-GFAP for astrocytes. 
The paraffin sections were deparaffinized, hydrated, washed 
three times with 0.1 M PBS, and incubated in the following 
order: 10% normal goat serum for 1 h at RT, rabbit polyclonal 
anti-Epo overnight at 4℃, and fluorescein isothiocyanate-
labeled goat anti-rabbit IgG (Sigma) for 1 h at RT. The 
sections were then washed and blocked with 10% normal 
goat serum for 1 h at RT, incubated with either ED1 (mouse 
monoclonal anti-rat macrophages), or anti-GFAP overnight 
at 4℃, and washed and incubated with tetramethyl rhodamine 
isothiocyanate-labeled goat anti-mouse IgG (Sigma). 
To minimize lipofuscin autofluorescence, the sections were 
washed three times in PBS at RT for 1 h each, dipped briefly 
in distilled H2O, treated with 10 mM CuSO4 in ammonium 
acetate buffer (50 mM CH3COONH4, pH 5.0) for 20 min, dip-
ped briefly again in distilled H2O, and returned to PBS. The 
double immunofluorescence-stained specimens were examin-
ed with a laser confocal microscope (FV500, Olympus, Tokyo, 
Japan). 
 
Treatment of animals 
Immunized rats were given recombinant human Epo (rhEpo, 
5,000 U/kg; Espogen, LG Life Sciences, Seoul, Korea) in-
traperitoneally for 7 consecutive days, either starting on 
day 3 PI (five rats) or on the day of clinical symptom onset 
(score ≥1, five rats). Control animals for rhEpo-treated EAE 
rats received vehicle (saline) alone from day 3 PI (five rats). 
In addition, three normal rats were injected intraperitoneally 
with rhEpo (5,000 U/kg), and three other normal rats receiv-
ed saline. The immunized rats were observed daily for clinical 
signs of EAE, and categorized according to the aforemen-
tioned stages. The progression of EAE was compared be-
tween rhEpo-treated and vehicle-treated control animals using 
Student’s unpaired, two-tailed t-test. In all cases, p<0.05 was 
considered significant. To study the protein expression in 
rhEpo-treated EAE, the spinal cord from one rat per group 
was sampled on day 15 PI. The spinal cords were removed 
and analyzed according to the methods described above. 
 
Results 
 
Increase in erythropoietin in experimental auto-
immune encephalomyelitis-affected spinal cords 
The level of Epo in the spinal cord was evaluated semiquan-
titatively by Western blot analysis during the course of EAE. 
Epo immunoreactivity was detected at low levels in the spinal 
cords of normal control rats (density, 0.118±0.03 OD/mm
2; 
n=3). Epo immunoreactivity increased significantly in the 
spinal cord during the peak stage of EAE (G.3, day 12 PI; 
0.298±0.017 OD/mm
2; n=3; p<0.05 vs. controls) and subse-
quently decreased during the recovery stage (R0, day 21 PI; 
0.206±0.002 OD/mm
2; n=3; p<0.05 vs. peak stage of EAE). 
However, the expression of Epo during the recovery stage of 
Fig. 1. Western blot analysis of Epo expression in the spinal cord 
of rats with EAE. Spinal cord samples were collected from normal 
control rats, rats at the peak stage of EAE (G.3, day 12 PI), and rats 
during the recovery stage of EAE (R.0, day 21 PI). Representative
photographs of Western blots; arrowheads indicate the expression 
of Epo and β-actin (upper). Semiquantitative analysis of Epo immu-
noreactivity in spinal cords, normalized to the intensity of β-actin 
expression in the same immunoblot. Epo was detected in the normal
controls, and its expression was significantly increased in EAE-
affected spinal cords. Data are (mean±SEM values) from three ex-
periments (lower), *p<0.05 vs. normal controls and the recovery 
stage of EAE, †p<0.05 vs. normal controls. PI: post-immunization, 
Epo: erythropoietin, EAE: experimental autoimmune encephalo-
myelitis. 
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EAE was still higher than the control level (p<0.05 vs. con-
trols)(Fig. 1). 
 
Localization of erythropoietin in spinal cord sec-
tions from experimental autoimmune encephal-
omyelitis-affected rats 
 
Erythropoietin immunoreactivity 
Epo was constitutively expressed in glial cells and neurons 
in the spinal cords of the normal control rats (Fig. 2A and B). 
During the peak stage of EAE (G.3, day 12 PI) there were 
many Epo-positive glial cells in the white matter of the spinal 
cord (Fig. 2C) and massive inflammatory cell infiltration into 
the parenchyma, where some round cells and neurons were 
positive for Epo (Fig. 2D). During the recovery stage (R0, 
day 21 PI), there were fewer inflammatory cells than during 
the peak stage of EAE, with only a few glial cells and neurons 
being positive for Epo (Fig. 2E and F). In addition, some 
Epo-positive vessels and ependymal cells were detected in 
the spinal cords of normal control rats and rats with EAE 
(data not shown).  
 
Identification of erythropoietin-positive cells in experimen-
tal autoimmune encephalomyelitis-affected spinal cords 
The patterns of Epo immunofluorescence in the spinal cords 
of rats with EAE were similar to those seen with single im-
munoperoxidase staining (Fig. 2). Epo (Fig. 3A, green) was 
abundant in ED1-positive cells (Fig. 3B, red; Fig. 3C, merge), 
suggesting that most of the macrophages were positive for 
Epo in EAE lesions at the peak stage. In addition, Epo (Fig. 
3D, green) was detected in GFAP-positive-astrocytes (Fig. 
3E, red) in the white matter (Fig. 3F, merge). 
 
Treatment with recombinant human erythro-
poietin affects experimental autoimmune enceph-
alomyelitis-progression and protein expression 
 
Recombinant human erythropoietin treatment ameliorates 
experimental autoimmune encephalomyelitis progression 
To examine the effects of rhEpo on the course of EAE, im-
munized rats were injected intraperitoneally with rhEpo, and 
the duration of paralysis in rhEpo-treated rats was compared 
with that in control EAE rats treated with vehicle (vehicle 
treatment on day 3 PI; 6.5±0.29 days). The duration of paral-
ysis was significantly reduced by rhEpo (early treatment, 
given on day 3 PI; 4.6±0.4 days; p<0.05 vs. vehicle), but there 
was no significant difference in the duration of paralysis be-
tween the rhEpo-treated and vehicle-treated rats on the day of 
clinical symptom onset (late treatment; 5.00±1.14 days). Fur-
thermore, both the early and late rhEpo treatment significantly 
ameliorated the clinical severity of EAE in comparison with 
vehicle treatment (p<0.05)(Fig. 4A).     
Fig. 2. Immunohistochemical staining of Epo in the spinal cords of normal control rats (A and B) and rats at the peak (day 12 PI)(C and D)
and recovery (day 21 PI)(E and F) stages of EAE. Epo was weakly detected in some glial cells (A, arrows) and neurons (B, arrows) in the 
spinal cords of normal control rats. Glial cells at the peak stage of EAE showed increased immunoreactivity for Epo (C, arrows). Epo-posi-
tive inflammatory cells (D, arrowheads) and neurons (D, arrow) were detected in the parenchyma. At the recovery stage of EAE, some in-
flammatory cells (E, arrowhead), glial cells (E, arrows) and neurons (F, arrows) were positive for Epo. Tissue from a rat at the peak stage of 
EAE stained without the primary antisera showed no staining (G). Counterstaining was with hematoxylin. Scale bars=40 μm. Epo: Erythro-
poietin, PI: post-immunization, EAE: experimental autoimmune encephalomyelitis. 
A  B  C
D  E  F G  
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Fig. 3. Immunofluorescent co-localization of Epo (A and D) with ED1 (B) and anti-GFAP (E) in the spinal cords of rats at the peak stage of 
EAE (day 12 PI). A large amount of Epo (A, green; arrows) was immunostained in ED1-positive macrophages (B, red; arrows)(C, merge; ar-
rows). Epo immunoreactivity (D, green; arrow) was co-localized in GFAP (E, red; arrow)-positive astrocytes (F, merge; arrow). Scale bars: A-F, 
20 μm. Epo: Erythropoietin, anti-GFAP: anti-glial fibrillary acidic protein, EAE: experimental autoimmune encephalomyelitis, PI: post-immuni-
zation. 
A  B  C
D  E  F
Fig. 4. Effect of recombinant human erythropoietin (rhEpo) therapy on the clinical course and protein expression in EAE. A: Rats were 
immunized with myelin basic protein and injected with saline (vehicle), rhEpo (5,000 U/kg) from day 3 PI (early group), or rhEpo from the 
day of clinical symptom onset (late group). Rats were scored daily for clinical signs of EAE. Data are the mean±SEM values from five 
animals per group. B: Western blot analysis of ED1 and Epo expressions in the Epo-treatment experiment. Spinal cord samples were col-
lected from normal rats that were injected with saline (lane 1), rhEpo (lane 2), and from EAE-affected rats (day 15 PI) that were injected with 
vehicle (lane 3), rhEpo from day 3 PI (lane 4), and Epo from the day of clinical symptom onset (lane 5). *p<0.05 vs. vehicle. EAE: experimental
autoimmune encephalomyelitis, PI: post-immunization. 
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Recombinant human erythropoietin treatment affects protein 
expression 
Western blot analysis of ED1 showed that immunoreactivity 
in the spinal cord was higher in the control EAE rats treated 
with vehicle on day 15 PI than in the normal control rats (Fig. 
4B). ED1 immunoreactivity was lower in EAE-affected rats 
treated with rhEpo than in vehicle-treated rats (Fig. 4B). Epo 
immunoreactivity in the spinal cord was higher in the normal 
rats treated with rhEpo than in the normal rats treated with 
saline (Fig. 4B). As shown Fig. 1, Epo immunoreactivity in 
the spinal cord was higher in the control EAE rats treated with 
vehicle than in the normal rats treated with saline (Fig. 4B). 
However, the Epo expression did not differ significantly be-
tween the normal rats treated with rhEpo, the EAE rats treated 
with saline, and the EAE rats treated with rhEpo (Fig. 4B). 
 
Discussion 
 
Summary of principal findings 
This is the first study to demonstrate that the level of Epo 
expression increases within the CNS during autoimmune in-
flammation. Based on the results of Western blot analysis of 
Epo expression, it is postulated that inflammatory cells and 
reactive astrocytes at the peak stage of EAE are important 
sources of Epo in the spinal cord of rats with EAE. The results 
of the present study also indicate that Epo expression in-
creases significantly in the spinal cords of EAE-affected rats, 
which suggests that Epo plays a key role in the amelioration 
of EAE. 
 
Significance of erythropoietin expression on as-
trocytes and inflammatory cells 
The present findings are in agreement with those of studies 
concerning Epo expression in ischemic brain injuries, show-
ing that astrocytes are one of the main cell types expressing 
Epo.
15,16 They suggest that Epo activates the neuronal Epo 
receptors and thus may inhibit hypoxia-induced apoptosis in 
neurons.
15 In the present study, we found that the expression 
of Epo increased in reactive astrocytes during the peak stage 
of EAE, suggesting that astrocytes protects neurons under 
cytotoxic conditions. 
In this study, we found that Epo was primarily localized in 
ED1-positive macrophages at the peak stage of EAE. This 
finding is very surprising in view of the general concept of 
macrophages in EAE. In response to stimuli, macrophages 
undergo a series of processes such as chemotaxis, phagocy-
tosis, and the release of inflammatory mediators that damage 
neuronal networks.
17 However, a previous study suggested 
that the production of several potent neurotrophic factors in 
leukocytes curbs the potentially neurodamaging consequences 
of severe CNS inflammation.
18 Therefore, the production of 
Epo by activated macrophages might be an important mech-
anism for neuron protection in EAE.   
 
Implications for recombinant human erythropoi-
etin therapy 
The administration of rhEpo decreased the clinical severity 
of EAE, and this effect was paralleled by a marked decrease 
in macrophage activity in the spinal cord. However, there was 
no significant difference in Epo expression between EAE-
vehicle and EAE-rhEpo treatments. As shown in Figs. 1-3, 
the activity of macrophages contributed to the increase in 
Epo immunoreactivity during the peak stage of EAE. Thus, 
we postulate that rhEpo transported across the blood-brain 
barrier into the spinal cord contributes to increased Epo 
expression. The onset of disease manifestation did not dif-
fer significantly between the early and late groups which 
we attribute to the use of an inadequate therapeutic dose and 
the timing of treatment initiation. Transferring this to the hu-
man disease where the starting point of autoimmunity can 
not be determined, it might be useful to apply neuroprotec-
tive treatment for longer than that the duration of acute neu-
rological deterioration. 
 
Assumption regarding the effects of erythropoi-
etin-apoptosis 
Increased Epo expression in EAE animals has not been dem-
onstrated previously, and therefore the effect of its expression 
on the inflammatory events associated with EAE is unknown. 
One interesting possibility for the effects of Epo on inflam-
matory cells comes from Trzonkowski et al., finding that the 
intensity of apoptosis in both CD4+ and CD8+ T cells at 
baseline was lower in hemodialysis patients than in healthy 
volunteers, and that it increased with rhEpo treatment.
19 In 
general, the initiation and termination of EAE pathogenesis 
involve T-cell and/or macrophage activation in the peripheral 
lymph nodes and CNS, and inflammatory cell apoptosis, re-
spectively.
20,21 Therefore, we do not exclude the possibility 
that the increased Epo expression at rhEpo administration or 
during the peak stage of EAE increases inflammatory cell 
apoptosis, which contributes to the suppression of EAE ini-
tiation or the acceleration of recovery.   
In summary, we postulate that the increased expression of 
Epo in EAE rats is closely associated with neuron protection 
and the activation of inflammatory cell death, which leads to 
the prevention of or functional recovery from EAE paralysis. 
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